UNBS-5162

CAS No. 956590-23-1

UNBS-5162( UNBS-5162, UNBS 5162, UNBS5162 )

Catalog No. M17690 CAS No. 956590-23-1

UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 45 In Stock
5MG 65 In Stock
10MG 122 In Stock
25MG 240 In Stock
50MG 402 In Stock
100MG 593 In Stock
500MG 1251 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UNBS-5162
  • Note
    Research use only, not for human use.
  • Brief Description
    UNBS-5162 is a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers.
  • Description
    UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. In vivo UNBS5162 after repeat administration significantly increased survival in orthotopic human prostate cancer models. Results obtained by the National Cancer Institute (NCI) using UNBS3157 and UNBS5162 against the NCI 60 cell line panel did not show a correlation with any other compound present in the NCI database, including amonafide, thereby suggesting a unique mechanism of action for these two novel naphthalimides.(In Vitro):UNBS5162 is a pan-antagonist of CXCL chemokine expression and exhibits weak antiproliferative activity against human cancer cell lines with mean IC50 of 17.9 μM. UNBS5162 markedly impairs PC-3 tumor cell growth kinetics, without inducing senescence, whereas the reverse feature is observed with respect to DU-145 cells. UNBS5162 is cytotoxic to a range of human cancer cell lines including glioblastoma (Hs683 and U373MG), colorectal (HCT-15 and LoVo), non-small-cell lung (A549) and breast (MCF-7), with IC50s of 0.5-5 μM. UNBS5162 also markedly increases the levels of expression of LC3-I and LC3-II in human cancer cells. UNBS5162 displays no anti-topoisomerase II activity. Moreover, UNBS5162 induces cancer cell death through lysosomal membrane permeabilization (LMP) in PC3 prostate cancer cells but not in U373 glioblastoma cells, with this LMP process occurring as an UNBS5162-induced decrease in Hsp70 expression. UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signaling pathway. UNBS5162 downregulates the protein expression of proteins associated with the PI3K/AKT signaling pathway, including the levels of phosphorylated (p)-AKT, p-mechanistic target of rapamycin kinase, ribosomal protein S6 kinase β1 and cyclin D1.(In Vivo):UNBS5162 (20 mg/kg, i.v.) increases the therapeutic benefits of taxol in vivo in the orthotopic human PC-3 prostate cancer model.
  • In Vitro
    UNBS5162 is a pan-antagonist of CXCL chemokine expression and exhibits weak antiproliferative activity against human cancer cell lines with mean IC50 of 17.9 μM. UNBS5162 markedly impairs PC-3 tumor cell growth kinetics, without inducing senescence, whereas the reverse feature is observed with respect to DU-145 cells. UNBS5162 is cytotoxic to a range of human cancer cell lines including glioblastoma (Hs683 and U373MG), colorectal (HCT-15 and LoVo), non-small-cell lung (A549) and breast (MCF-7), with IC50s of 0.5-5 μM. UNBS5162 also markedly increases the levels of expression of LC3-I and LC3-II in human cancer cells. UNBS5162 displays no anti-topoisomerase II activity. Moreover, UNBS5162 induces cancer cell death through lysosomal membrane permeabilization (LMP) in PC3 prostate cancer cells but not in U373 glioblastoma cells, with this LMP process occurring as an UNBS5162-induced decrease in Hsp70 expression. UNBS5162 inhibits the proliferation of esophageal cancer squamous cells via the PI3K/AKT signaling pathway. UNBS5162 downregulates the protein expression of proteins associated with the PI3K/AKT signaling pathway, including the levels of phosphorylated (p)-AKT, p-mechanistic target of rapamycin kinase, ribosomal protein S6 kinase β1 and cyclin D1.
  • In Vivo
    UNBS5162 (20 mg/kg, i.v.) increases the therapeutic benefits of taxol in vivo in the orthotopic human PC-3 prostate cancer model.
  • Synonyms
    UNBS-5162, UNBS 5162, UNBS5162
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PARP
  • Recptor
    CXCL
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    956590-23-1
  • Formula Weight
    326.35
  • Molecular Formula
    C17H18N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 21.5 mg/mL. 65.88 mM;
  • SMILES
    CN(C)CCn1c(=O)c2cccc3cc(NC(=O)N)cc(c1=O)c23
  • Chemical Name
    1-(2-(2-(dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin-5-yl)urea

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Mijatovic T, et al. Neoplasia. 2008 Jun;10(6):573-86.
molnova catalog
related products
  • E7016

    E7016 (GPI 21016) is an orally available PARP inhibitor that inhibits DNA repair and enhances tumor cell radiosensitivity both in vitro and in vivo.

  • MK-4827 Racemate

    MK-4827 Racemate is a selective PARP1 and PARP2 inhibitor with IC50s of 3.8 nM and 2.1 nM, respectively, over 330-fold selectivity for PARP3, V-PARP and Tank1.

  • BSI-201

    BSI-201 (Iniparib;NSC 746045;IND-71677;SAR240550) is a potent, small molecule PARP1 inhibitor with strong anti-neoplastic effect.